Skip to content

Study of abnormal glucose metabolism and risk of atherosclerotic cardiovascular disease in patients with nonalcoholic fatty liver disease and analysis of related factors

Study of abnormal glucose metabolism and risk of atherosclerotic cardiovascular disease in patients with nonalcoholic fatty liver disease and analysis of related factors

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400087773
Enrollment
Unknown
Registered
2024-08-05
Start date
2023-08-25
Completion date
Unknown
Last updated
2024-08-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-alcoholic fatty liver disease

Interventions

Normal glucose metabolism group/abnormal glucose metabolism group:None
ASCVD high-risk group/ASCVD non-high-risk group:None

Sponsors

Zhejiang Provincial People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 76 Years

Inclusion criteria

Inclusion criteria: (1) From January 2010 to December 2022, patients attending Zhejiang Provincial People's Hospital and Hangzhou Normal University Affiliated Hospital for liver puncture; (2) All patients met the diagnostic criteria for diabetes/pre-diabetes in the "Chinese Expert Consensus on Intervention for Adults with Prediabetes" published in 2023 and the "Chinese Guidelines for the Prevention and Control of Type 2 Diabetes (2020 Edition)". (3) All of them met the diagnostic criteria for diabetes/pre-diabetes in the Chinese Guidelines for Prevention and Control of Dyslipidemia in Adults (2016 Revision).

Exclusion criteria

Exclusion criteria: (1) Hepatic puncture patients without NAFLD (2) Patients with missing clinical data during hospitalization for diagnosis of glucose metabolic status, inability to conduct 10-year ASCVD risk assessment, and day hospitalization. (3) Patients with pathology results that do not specifically describe steatosis, inflammation, and fibrillation (3) Patients with pathologic findings that do not specifically describe the severity of steatosis, inflammation, and fibrosis. (3) Pathologic findings that do not specifically describe the severity of steatosis, inflammation, and fibrosis (4) Patients <18 years of age (5) Patients with concurrent primary or secondary hepatocellular carcinoma.

Design outcomes

Primary

MeasureTime frame
FPG;

Countries

China

Contacts

Public ContactXiaohon Wu

Zhejiang Provincial People's Hospital

drxhwu@163.com+86 138 1587 0351

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026